Transcript

Today we're talking about immunology, as you may recall. Let's roll. Yes, let's roll. Uh, and by the way, admire your little finger because most of the planet isn't as gifted as you are. Not everyone was guaranteed so many brains as you and I say seriously have been fortunate enough to have been given to granted. Let me just finish up discussing what we were talking about last time which was the cell cycle. You may recall that we talked about enco genes. We talked about RAS and the RAS enko protein which sends out miogenic signals and what it does just to summarize what we were talking about is it pushes cells from the beginning of the G1 phase of the cell cycle up to a point here a decision point in the life of the cell.

It's called the restriction point. And here, just by way of review, the cell has to decide whether or not it's going to commit itself essentially irreversibly to go through the rest of the cell cycle or when it's whether it'll stay in G1 and may even retreat from the cell cycle into G0. And RAS pushes this decision forward. The retinol blastoma protein, which we talked about the last time, stands as the guardian of the gate right here, the RB protein. And the retininoblastoma protein holds this gate shut unless and until certain preconditions have been satisfied on which occasion the retinol blast protein opens up the restriction point gate and allows the cell to go through the rest of the cell cycle.

And now when viewed from this perspective, we can begin to understand how hyperactivity of RAS and how the inactivation of this RB this retinino blastto tumor suppressor protein have such disruptive destabilizing effects on the proliferative controls of the cell. Uh keep in mind this is a negative actor on cell proliferation. Um it's a tumor suppressor gene which must be inactivated in many cancers. This is a protoonco gene or an anko gene which must become hyperactivated. Now I want to move from that into the topic of today and that's uh the whole issue of immunity and much of our immunity comes from understanding the way we deal with viral infections.

The fact is just to cite one arbitrary viral infection relatively few people die from viral infections these days because we can become immunized against them. The first immunizations already began in uh the uh late 18th century, believe it or not, when a physician in England called Edward Jenner uh first noticed that women who had worked uh as milkmaids milking cows and who got a disease called cowpox from milking the cows seemed to be immune to the disease of smallpox which was by that time realized to be spreading epidemics. a highly infectious agent and one which actually killed quite a few people.

And Jenner intuited correctly in retrospect that the experience of these uh milkmaids um and their exposure to cowpox virus somehow protected them gave them indeed lifelong protection from subsequent uh smallpox infection. Subsequently to that uh the um uh the soores from the cowpox infection were scraped and and the exodate the um the fluid was used was scratched into wounds of people um in order to immunize them. And so immunization already began in the 1790s, taking a soar from the skin of a cowpox infected patient, injecting that into the um the skin of somebody who required immunization and as a consequence hoping that this would confer them lifelong protection.

In some cases actually the individuals who were infected in that way actually came down with small pox uh in other or some virulent form of this cowpox. But in most other cases, these individuals actually acquired a lifelong immunity. In fact, the very word vaccine which uh was used already at the time comes from the Latin word uh vakus which means a cow. And um in the north side of Cambridge Common there's a the Benjamin Waterhouse uh house which is still there. um he was the first physician to introduce uh smallox vaccination into this country already in uh the end of the 18th century. If we fast forward to a situation like polio virus, we have situations in this country where in the 1940s, 1930s, 1940s there were epidemics of polio virus.

If one began to examine um who was susceptible and who wasn't, it was clear that people um children who were for example um born and raised in uh middle and upper middle class uh dw houses were very susceptible through much of their lives. For example, in Southern California, there were dramatic examples whereas children who grew across grew up across the border in let's say Tijuana, Mexico um rarely came down with paralytic polio. The polio virus uh as one soon learned was a virus which infects not only the gastrointestinal tract and creates a form of mild diarrhea but in maybe one out of a hundred persons the virus escapes from the GI tract from the gastrointestinal tract invades into the central nervous system and um actually creates debilitating um uh paralysis which most of which is is not healed.

Uh and some people have lifelong um paralysis. other individuals whose paralytic paralysis uh goes away actually when they grow older 30 40 50 years later they begin once again to experience the paralytic symptoms that arose as a consequence of their childhood infection and at this time um one began to try to figure out why uh children living in Tijuana Mexico rarely came down with polio virus uh infections whereas those who grew up up north let's say in southern California did did indeed do so. And one came to the conclusion that the children growing up in Tijana, Mexico were frequently exposed very early in their life to contaminated water, sewage contaminated water, and they as a consequence acquired a a lifelong immunity without getting sick.

Whereas children who grew up under rather sterile conditions further north had any exposure to the virus and when it hit them as uh young adults or as teenagers, it created devastating effects. And this indicates once again that somehow one's exposure to an infectious agent, historical exposure, has a dramatic effect on one's subsequent susceptibility to um the um uh the to a virus. And in the case of polio virus, we're dealing here with an agent um which is much simpler than the retroviruses we talked about last time like RSV. Polio virus also has a singlestranded RNA genome and that's encapsulated in a proteinatious coat uh which is uh made up of only of viral proteins.

So it's very simple singlestranded RNA proteinatious coat. The singlestranded RNA is actually polyadenilated at the threep prime end. So it can serve as a messenger RNA. It's of the same polarity that is it has a plus polarity which means that it can be translated immediately. I'm distinguishing that from the other flavor of singlestranded RNA which could be of the complimentary strand which could exist because one can make double stranded RNA which obviously cannot be translated. So this can serve as a messenger RNA and just as an aside the way that polio virus replicates is totally different from that of retroviruses.

What happens is that polio virus makes its own polymerase. You go from singlestranded RNA to doublestranded RNA i.e. the complimentary copy is is made and that in turn is used as a template for making more singlestranded RNA progeny RNA and note here that there's no DNA at all involved. In fact, polio virus can grow inside a cell that has been deprived of its nucleus. Moreover, if one stops nuclear RNA uh nuclear DNA dependent transcription, that has no effect on this. But you'll you'll notice correctly that these these kind of steps here involve RNA dependent RNA polymerases and in the normal physiology of a cell that such a polymerase such an enzyme never operates and therefore polio virus must make among its other proteins an RNA dependent RNA polymerase that can mediate these steps.

making a complimentary copy of this strand to get uh to get to the complimentary strand and then making progeny plus strand RNAs. Again, it has a very simple capsit of of several viral proteins which wrap it up. Now, if one wants to assess the potency of polio RNA, one can grow it in a petri dish. One way of figuring out how much polio virus RNA is in a solution is to make a monollayer of cells like this and then take various dilutions of a virus stock. And when one talks about a virus stock, one talks about a a solution of virus particles. One can't really see them. And even if one could see them under the electron microscope, one wouldn't really know what fraction of the ones you were seeing were actually biologically competent.

But most uh interestingly you can take polio virus a solution of polio particles place it on a monollayer of cells here which can be infected by polio virus. In contrast to what I told you last time about RSV where an infected cell can tolerate the continued presence of a viral infection without dying. Polio virus is a highly cytoathic virus and by that I mean it replicates inside cells and it kills them during the course of replicating inside these cells. So here what one has is just a polio virus will infect a cell here and then it will begin to infect spread from that cell to neighboring cells in the in the surrounds and in so doing it will create it will erode a hole right here in the monollayer whose presence a so-called plaque signifies the fact that there was an initially infecting virus particle there that spread centrifically that spread outward from the initially infected cell in detail.

If you want to do this experiment really nicely, what you do after you infect the initial monollayer of cells, which I show here in section is you put on a layer of aguros or something above the infected monollayer and that ensures that if there's any viral spread, it will be from cellto cell spread in a certain neighborhood rather than virus particles getting into solution and swimming around all over the plate and infecting uh cells helter skelter. So here we might want to infect an initial cell right here in the monollayer. And now this aguros will confine the the subsequent spread of progyny virus to adjacent cells in the area.

Again eroding ultimately a hole here which we call a plaque. And uh if we count the number of plaques that will tell us how many biologically active virus particles there were in the initial solution that was previously applied to that monollayer culture of susceptible cells. One can use such monollayer cultures in fact uh to propagate polio virus and one can take the polio virus coming out of those monollayer cultures and actually use them to inject into human beings in order to vaccinate them to confer on them immunity. But if you do that with wild type polio virus then uh what will happen is that you may inadvertently give that person whom you're attempting to immunize a nasty polio infection which could paralyze them might even kill them.

Uh when I was growing up uh polio virus infections were were much dreaded because we knew of people who were being kept alive in iron lungs that breathed for them because their autonomic nervous system had been destroyed by a polio virus infection. So uh what happens is therefore if one wishes to immunize somebody if one wishes to vaccinate them against polio virus one needs to make inject them with an attenuated virus that is a virus whose ability to create disease whose pathogenic abilities pathogenic remember refers to the ability to create disease. You want to use an attenuated virus which might be able to go into the body.

It might be able to evoke immunity but it will not create a major disease response. And this was dealt with uh in two different ways. Sulkq Jonas Sulk one of the uh pioneers of creating a polio virus vaccine took the polio virus particles that had been produced by culturing them on monollayers of monkey kidney cells and he treated the polio briefly with a little bit of formaldahhide. And formaldahhide as you may know reacts with the aman groups of um the uh of the ribonucleotides of the of the sum purines and perramitines and therefore kills the virus and that killed virus having been treated briefly with uh the formaldahhide.

The virus particle is still essentially intact was then injected into individuals. Alternatively um his deadly rival deadly rival because they two hated each other. They hated each other's guts. Sabin decided on another uh strategy for making a vaccine stock and that is he took polio virus which had been passage from one cell culture to the next over extended periods of time over several years. So it had been passed in vitro and when we say in vitro in this context we mean it had been t polio virus had been taken from one plate put into another plate of cells taken to another plate of cells. In vitro here implies in culture rather than the other uh alternative in vivo means that the virus is being paged in a living organism.

And as it turns out when you passage polio virus in vitro from by passing it just from one culture of cells to the next infecting one after another in a serial or sequential fashion then the virus is selected for its ability to proliferate in the cultured cells in vitro but it gradually loses its ability to create disease in vivo in that there is no Darwinian selection to favor its disease-causing ability and consequently virus that Sabin used wasn't inactivated with um with uh formaldahhide. It was simply attenuated because of extensive in vitro propagation. And when he uh injected that into young people uh very rarely did they ever come down with polio virus infection and the virus was able to replicate to some extent in their bodies without causing the disease and to create lifelong immunity i.e.

such an individual was protected from subsequent polio virus infection ever again. And uh as it turned out, this was a very nice uh way of protecting things. As it also turned out, the monkey kidney cells that were used to propagate the virus also contained certain monkey viruses. For example, there was a a it came out after years that there was a DNA tumor virus. We've been talking about RNA tumor viruses until now, but there's a DNA tumor virus called SV40, which is a very potent tumor virus in hamsters and mice and rats. And it turns out that SV40 lingered. It lurked in monkey kidney cell cultures.

And whenever you nobody knew about it, whenever you put polio in in many of these cultures, not only did polio replicate, but all of a sudden so did SV40. And therefore many of the stocks of polio virus that were used to inject people like myself. I lived around the corner in Pittsburgh from Jonas Sulk and the the children in the Pittsburgh public schools were his first guinea pigs. Mere were exposed to polio virus stock which actually had more SV40 particles in it than polio particles because of this inadvertent contamination. there probably were between 30 and 40 million people who were immunized with polio virus and inadvertently with S340 virus.

Uh and one has done epidemiology in the subsequent years to figure out whether that had led to any increased rate of cancer because it could well have. There could have been an epidemic of cancer in this country. Millions of people affected because of this unknown and at the time almost unknowable contaminating virus. Uh as it turned out, people who were in infected with S340 uh inadvertently have no higher rates of cancer than anybody else. Even though this um virus is a very potently tumoric virus like RSV, but doing so uh in this case in rodent cells and ostensibly not in humans. So public health measures can sometimes have unforeseen side effects or consequences that nobody anticipates ahead of time.

Now getting back to the whole strategy of polio virus infection, this raises the issue of what it was in the polio virus that was able to evoke the subsequent lifelong immunity. And in telling you that I I mentioned the following you can make anti- serum from or you can make serum from a individual who's been immunized with polio virus and recol recollect we we've mentioned this before the way to make serum is to allow blood to clot the red cells and the platelets aggregate in the bottom and what remains on top is simply serum. can spin out all the residual cells. And so all you get is sort of a straw colored fluid.

And that serum from um an individual who's been immunized with um polio virus stock can actually be used to you can add it to the polio virus stock prior to adding these virus particles to the petri dish. So here's the petri dish as before. And what you find is that if you add serum from a polo from an individual who's been immunized to the polio to a solution of polio virus particles and then you take that mixture and put them on the plate, you no longer get any of these plaques that I referred to before. And that indicates that within the serum there is some kind of factor which is neutralizing the infectivity of the polio virus particles i.e.

the polio virus particles are in some way um prevented from creating an infection and their plaque forming ability their ability to to uh corrode these holes in the monollayers of subsequently infected cultures is now compromised and such um activity suggests the that that such an individual has actually anti- serum i.e be some kind of reactivity which prevents the polio virus particle from doing its thing. In fact, I can tell you that such anti-erum or such neutralizing uh antiserum can be achieved in a number of ways. One way to do it is just to take the protein capsid the outer coat of the polio virus particle that I described before and inject that into an individual and that will on its own already evoke a measure of antiviral immunity.

It will also it will evoke a concentration of anti- serum in the blood of of a patient. Or if you want to do it in a very much more modern way, you can sequence the proteins of the polio virus and determine the amino acid sequence. And when you do that, you can synthesize through organic synthesis olopeptides of 10 or 20 amino acids long. And these olopeptides reflect different parts of the polio virus coat protein. So if here's the sequence of one of the capsid proteins. Recall that capsid refers to the coat that's that's shielding or protecting in this case of polio virus the singlestranded viral RNA genome.

So if here's one of the capsuid proteins, what you can do is to figure out the amino acid sequence of this segment of the capsuid protein and then rather than cutting it out from the capsu protein, you just synthesize it by or organic synthesis 10 or 20 amino acid residues long and when you inject that oligopeptide into an individual that may also evoke some kind of neutralizing antibbody response. In fact, um, as you might correctly imagine, if we can look in more detail at the capsid structure, I'm just going to draw it in a very primitive way here. It's it's obviously much much more complicated, but if this is the capsid here, it has an inside and an outside.

And the the uh antibodies that you make against a an olopeptide that is sticking out here on the outside will be neutralizing i.e. um the antitheserum will be able to recognize the outside of the virus particle and somehow inactivate it. But if you were to make a um use an oligopeptide antigen from over here which might be a part of the capsu protein that is deep inside. Well, even though um you might have a good reactivity with this oligopeptide, it would not be neutralizing. And that suggests the notion that whatever is present in the anti-erum is recognizing some etern external portion of this protein which is sticking out and that external portion is called an antigen.

So there's a specific chemical structure which is being recognized by the anti-erum and we call that an antigen. In principle there are dozens of distinct antigens on the surface of a polio virus particle. Um each of which one can in principle make an immunizing antibbody against each of those one can therefore consider to be an antigen. And how can we imagine this anti-erum is actually successfully neutralizing the uh the virus particle. And here this depended on actually the biochemical characterization of anti-era because one soon came to learn that within antisa are what we call antibodies or keep in mind that in in biology you never should ever use a simple Anglo-Saxon word if you can use a much more complicated Greek or Latin one.

So we can always call these imunoglobulins. You see the word right there immunoglobulin represents an antibbody molecule. And it turns out that there that much of the protein in the soluble fraction of of um our uh our serum is cons consists of such antibbody molecules. And these antibbody molecules have a very interesting structure which I'd like to um dwell upon momentarily. But before I do that, I just want to anticipate what I'm about to say by indicating that we now realize that an antibbody molecule can recognize an antigen on the surface of the virus particle and the antibbody molecule can actually physically bind to this antigen.

So we have an antigen antibbody complex and that binding of the antibbody molecule to the surface of the virus particle is what results functionally in the neutralization of its infectivity. Or to put it another way, I given the fact that this particular capsu protein might be repeated, let's say 60 times around the spherical surface of a virus particle, there might be in fact 60 different antibbody molecules recognizing this repeated antigen which occurs on each of these capsid proteins. And therefore, you can imagine in a very approximate way that if you have an effective neutralizing antibbody, it's coating the surface of the virus particle with antibbody molecules.

and that clearly obstructs the ability of the virus particle to initiate a subsequent round of infection. Here's what a single antibbody molecule looks like and it has some critically important features. First of all, there is a specific region of the antibbody that recognizes the antigen. In this case, I'm using as the example of the antigen an olopeptide on the surface of uh the the um polio virus particle. And that is located in this part of the antibbody molecule. Note by the way the antibbody molecule is a heterotetrome. It has two uh light chains, two small chains here on the right and two heavy chains.

Note that the cyine dulfide bonds are holding the entire assemblage together. So here one is not relying on hydrogen bonds to hold together this heterotetimer. And note the following that there are portions of the antibbody molecule which may be uh specifically varied from one antimic molecule to another over here and other portions which are standard operating hardware and let me elaborate on that for a moment. If you look in the um serum of an individual and you try to analyze the chemical structure of the antibbody molecules in their serum, you find that for a given type of antibbody molecule like this, all the antibbody molecules share this constant here, light uh light purple domain.

They all have that in common. They all have in common also the light blue domains. But if you were able, and we'll discuss this in a moment, how you could do so. If you were able to um analyze the this other portion, you would find that when you look at one antibbody molecule, it has a certain amino acid sequence here which is involved in antigen recognition and that this amino acid sequence on the light and heavy chain varies from one heterotetimer to another heterotetimer. And again I'm going to reinforce that but I I want to indicate that there are within the human uh anti-erum millions of structurally distinct antibbody molecules.

They share in common the structure down here up to this point and thereafter they have each of them has its own idiosyncratic its own unusual its own particular private antigen recognition site which stems from a region or a pocket of the protein which is involved in antigen recognition and has variable amino acid sequences. Here you see the way that an X-ray crystalallographer would actually visualize this molecule. And you begin to realize that the schematic that I showed you before um in fact is uh is really doing a little bit of violence to the real amino acid sequence uh to the real threedimensional structure.

Excuse me. Now note something else that is implicit in what I've just said, but I haven't said it explicitly. There are actually two antigen recognition sites, one here and one here. So this antibbody is in that sense bvevalent. And if there were, for example, um, two polio virus particles, one over here and one over here, you could imagine in principle, although I'm not drawing things to scale, that this antibbody molecule could actually bind, use one of its antigen recognition sites to bind over here to one polio virus particle and this to bind to another polio virus particle. Now I've told you that the antigen that's recognized by this antibbody is an oligopeptide which constitutes a distinct chemical structure.

How many different oligopeptides of 10 amino acids long are there in the mathematical universe? How many conceivable ones are there? How many amino acids are there? 20. So what's the number? I heard you all say 10 to the 20th, right? So that's an awful lot. That's more than you can shake a stick at. So that means that there are in principle essentially an infinite number of olopeptides of 10 amino acids long and each one of those could in principle constitute a distinct antigen that could be recognized by the antibbody molecule. Note that what's happening here is that a protein antigen such as one of these olopeptides is being recognized by another protein which is the antibbody molecule.

And therefore we begin to imagine there's some kind of lock and key complementarity where somehow the amino acid sequence here recognizes and binds in a complimentary fashion to the antigen that is being recognized and there's a physical association which allows the antibbody molecule then to attach tightly to the antigenbearing uh polio particle. And by the way, uh to put it another way, it could be that some of these polio virus capsu proteins have not yet been assembled in a virus particle. And even if they aren't, in principle, a free particip molecule and be bound by the antibbody molecule.

Now, this creates um a uh several major conceptual problems. How on earth can the uh body make antibbody molecules that are able to recognize a polio virus particle? Well, you'll say that's easy. Clearly, in our genes, there must be some kind of uh nucleotide sequence which has up here the ability to encode an antigen binding site. Note, by the way, the antigen binding site is actually composed of two different proteins. Here's part of the antigen binding site. Here's other part of the antigen binding site. So it must be on two different genes. But these two different genes create an antigen binding site which can recognize polio virus.

Bind the polio virus antigen and neutralize it. Well, that's well and good. That's perfectly reasonable. But let's tell let me tell you what's unreasonable that about that. Each of us during his or her lifetime are going to be infected by literally hundreds of viruses. you get cold viruses almost every uh couple two, three, four, five times a year. By the time you get old, um you actually have acquired immunity to many of these. But during the course of one's lifetime, one has been able the immune system has been able to generate antiviral immunity and eliminate virtually all the viral infections you ever got.

How many people do you know who've actually died of a viral infection? And yet each one of these viruses is in principle able to replicate throughout your body and kill you and they never do. So that means that the immune system is extremely effective um in uh developing an antibbody or antibodies which can neutralize infecting virus particles. You might have the cold for a day, a week or two weeks, but eventually the immune system develops enough antibodies and other strategies to eliminate the viral infection from your body. I remember when my grandfather was 94 years old and he got a cold and he hadn't had a cold for 20 years because by the age of 75 he had been exposed to almost every virus imaginable.

And so when he got a cold at the age of 94 his brain was still working. He'd forgotten how to blow his nose. It just hadn't happened to him. He doesn't know what it like to have a cold anymore. Um so it just goes to show you that the immune system can be very versatile and very successful. But this creates a major conceptual problem. How does the how do our genes know how to create antigen binding sites in our antibodies that recognize all of the infectious viruses that are going to attack us during a lifetime? Do we have a gene for neutralizing smallpox? Do we have a gene for neutralizing polio virus and adno virus which gives us bad head colds and um uh we rabies virus and viculous stomatitis virus and all other kinds of viruses that we're going to experience in a lifetime.

Well, possibly we do have a gene for each one of those. But then I'm beginning to raise some other questions if you believe that which you shouldn't. First of all, there are many different distinct olopeptide antigens on the surface of the polio virus particle. If you look at the that the antibodies that have been developed against the polio virus capsid protein in an immunized individual, they have one antibbody that that recognizes one part of the capsid protein and another antibbody that recognize another part. So here's the the surface of the capsid protein blown up now. And we can imagine there are different oligopeptide epitopes on different parts of the protein and they're all 10 10 amino acids long for example.

The fact is in individuals who have antipolio virus antibbody you can find that there are there's an antibbody that recognizes this epi this anti um antigen and one that recognizes this antigen and another that recognizes this antigen. So the number of distinct antigens which the immune system has succeeded in making antibodies against vastly exceeds the number of infectious agents we're going to experience in a lifetime. And that begins to undermine your confidence in the notion that when we're born we already possess the genes to recognize different infectious agent and to construct neutralizing antibodies against them.

There's also another flaw in this whole notion that we inherit a set of genes that enable us from the get-go to make specific antibodies. And that flaw comes from the following notion. Evolution cannot anticipate which infectious agents each one of us is going to experience in a lifetime. Let's say that some of us um experience a totally new kind of viral infection which had never been experienced by our ancestors. If the way of neutralizing and and defend that virus and and defending us against that infection depended on using an antibbody molecule whose sequence was encoded in our germ line in the genes we inherited at birth then we might be in bad shape if that virus was a novel virus to which the human race had never been exposed.

And I in arguing that I'm telling you that we cannot uh it's impossible to imagine a situation where our germ line the set of genes we are born with that we start life with already contains the information for making each one of the different kinds of antibodies that are in our anticerum. How many different kinds of antibodies are in our anticerum? Well, now the whole uh notion becomes even more stark because there's probably millions maybe even 10 or a hundred million distinct antibbody molecules floating around in our blood. Each one in this case has the same constant region. Down here you see the constant region and each one of these 100 million distinct antibbody species has its own antigen combining site.

Now if we want to pursue that further we have to begin to imagine how the immune system can make so many different antibbody molecules. This itself is a major conceptual challenge. And now we have to go into a little bit of cell biology because if we look at the uh immune system and there are cells forming the immune system, we find a set of cells that are called B cells or a subset of B cells that are called plasma cells. And the plasma cells and there's a whole bunch of different plasma cells. The plasma cells are floating around in the circulation. And the plasma cells are able to secrete antibbody molecules into the serum.

And they they are abundant. They're around by the billions inside our our body. And these plasma cells are constantly secretting antibbody molecules into the serum around them into the plasma around them. And these are the antibbody molecules I've been talking about here. These are the antibbody molecules that are capable of neutralizing polio particles. So this now creates a another conceptual question. Let's imagine for the sake of argument there are that in our bloodstream there are 100 million distinct antigen species floating around. And when I say I don't mean 100 million molecules I mean there's 100 million molecules um there's a million molecules and each one of these species has a different antigen binding site.

So there may be many antigen binding sites. There may be u many antibbody molecules. There may be millions of this kind of antibbody that recognize this antigen. There may be millions of this antibbody recognizing this antigen. Millions of this antibbody recognizing this antigen on the surface of polio virus. And I'm saying there could be a million distinct species of antibodies. Each species being defined by the antigen it recognizes and by the structure of its antigen recognizing site, its antigen binding site. In other words, to repeat myself, what distinguishes one species of antibodies from another is the amino acid sequence, the structure of this particular region of the antibbody molecule.

That makes one species of antibbody different from the other. And with all that in mind, we have two alternative scenarios. Let's again say there's a million different species of antibodies being secreted into the anti-erum at any one point in time. This cell could make all million. This cell could make the whole million species. this cell could and this cell could in other words each one of these B cells could be multi-talented able to simultaneously make a million different kinds of antibbody molecules the opposite con opposite model is as follows and that is that this species makes uh this B cell makes one species of antibbody we'll call it antibbody A and this species makes another species of antibbody mo this uh B cell makes another species of antibody molecule.

So this B cell makes antibbody A. This B cell makes antibbody B. This B cell makes antibbody C. And keep in mind that when I'm saying antibbody A, B, and C, I mean A has a certain antigen binding site. B has another antigen binding site. C has yet another antigen binding site. And we can distinguish between these two alternative mechanistic models by looking at the disease called multiple myyoma. And what you have in multiple myyoma is the following. All of a sudden the bloodstream becomes full of much greatly elevated levels of antibbody molecules. They're present in the bloodstream. Now normally if you look at all the antibbody molecules in the bloodstream and you were to separate them by some kind of electrofaretic technique which distinguish them on the basis of subtle differences in amino acid sequence and let's not worry about exactly how you do that but we've talked about a million different antibbody species.

They're chemically slightly different from one another by virtue of the antigen recognizing site. And if you could separate them by some kind of system that separated them the basis of their charge, you'd find a whole spectrum of different antibbody molecules, a million in this large heterogeneous mixture of antibbody molecules. Each one each species found somewhere or another in this very broad distribution of a 100 million distinct species which are all or a million distinct species which are all mixed together in the anti-erum. If you look at the serum or the plasma of a patient suffering from multiple myyoma, what you find is the following that one species of antibbody molecules dominates over all the other ones.

And so now whereas that a single species may only be on average 1 millionth of the total total antibbody complement in the blood in those suffering from myoma or sometimes it's called multiple myyoma. Now one single antibbody species may represent 60 70 or 80% of all the antibbody molecules in the blood and clearly something has gone very wrong. And if you look at what happened in the case of um an individual multiple myyoma, if we look at that diagram up there, what you see now is that instead of there being many different B cells that are equivalently represented in the bloodstream, now one of the B cell types has begun to multiply uncontrollably.

And this particular B cell type, which I indicate up there, which happens to be specifically able to make antibbody C in this model. Now this particular species of B cells is now a predominant constituent of the population of B cells in the blood. So just to reiterate in the normal blood there there are million different subpopuls of B cells but in these individuals one of the subopul of B cells has expanded. It's created a monoconal growth. Keep in mind monoconal refers to the fact that all the cells in this tumor and it is a tumor descend from the same ancestor. So it's a monoconal growth. It's it's a kind of cancer.

It's a kind of blood cancer. And all of the cells in this population make the identical antibbody molecule which explains this very homogeneous peak here riding above the very heterogeneous mixture of antibodies. The background heterogeneity that normally characterizes normal serum. And what that clearly indicates is that each different B cell or plasma cell as you will like to call it in our normal serum is specialized to make its own particular kind of antibbody. It's not that a single B cell can make a million different antibodies. Each B cell makes a very specific kind of antibbody. And when I say a specific antibbody or a specific antibbody species, again, I'm referring to an antibbody that has a specific antigen binding site.

Or to put it another way, all of the antibbody molecules coming out of a single B cell are identical with one another. That then raises the question of how the B cell learns how to make that antibbody molecule and not other antibbody molecules. There's yet another puzzle we have to answer and that's the following. If you look at the serum response of an individual to a viral infection, it looks like this. And here, let's look at what's present in the ordinate and it's on a log scale as you can see here and what's present on the obsa. If one is initially exposed to an antigen and develops an an immunity then here is the wave of antibbody production and the concentration of antibbody against let's say polio virus that is present in the blood of a recently infected individual.

They're exposed to the antigen or in this case the polio virus capsit protein. In the the days and weeks that follow they develop a significant level of antibbody which is used to neutralize in this case the infecting polio virus particles and then once the polio virus is cleared from the system i.e once all the infectious agents the infectious particles have been neutralized then the antibbody molecules go down almost to zero and there's virtually no antibbody against polio virus left around. But look what happens when that individual is reexposed to polio virus years later. All of a sudden now they he or she mounts a massive antibbody response vastly higher than the initial one.

Well, you'll say it's only two-fold higher than this. But let's look at the ordinate. This is a logarithmic plot. So on this plot the second secondary antibbody response is maybe a 100 or 200 times more vigorous much higher antibbody uh production. Let's think about this time years later when that person is exposed to a second virus. Let's say that person is exposed subsequently to another to a cold virus adn noirus. Does the exposure to polio virus here help in the blue curve help that person develop an adnoirus antibbody response? The answer is absolutely not. There's no cross immunity. And so when that individual year later becomes exposed to adnovirus, there's once again the same kind of initial response that happened in as a consequence of previous leaks being exposed to polio virus.

It's a rather weak response. It's effective enough in developing the initial im um tumor of a virus eliminating ability, but it's not very strong. What is this telling us? I'm glad I asked that question. It's telling us that the immune system is able to remember over a period of months, years, and decades that a previous exposure to this antigen has occurred. Because here the the immune system in the second red curve knows somehow remembers that there was an exposure years earlier. And not only does it remember and respond rapidly, but it responds much more vigorously. And here now we begin to recognize some of the outlines of immunity because the immune system remembers this earlier exposure.

And when it and when it's provoked a second time through an accidental and inadvertent exposure to polio virus on a second occasion, now it really goes to town and now it creates antisirere which is much more vigorous than it was during the first exposure. If the first exposure had never occurred, there wouldn't be such a vigorous response. Look at this one over here. So now we begin to realize two mysteries that we have to explain next time in our further discussion of the immune system. First of all, how do B cells figure out how to make so many different kinds of antibbody molecules? And secondly, how does the immune system remember from one decade to the next that an exposure to a previous antigen has occurred which merits a vigorous response.

See you then on Friday.